Business
DOCM: Rx and TeleClinic growth, margin gains, and robust funding support a positive 2025 outlook
DOCM: Rx and TeleClinic growth, margin gains, and robust funding support a positive 2025 outlook
About this update from Docmorris Ltd
Strong Rx and TeleClinic growth drove a 10.2% revenue increase in H1 2025, with gross margin up 70 bps and a solid balance sheet after a CHF 200 million capital raise. Full-year guidance is confirmed, with sequential EBITDA improvement expected as marketing spend is optimized. Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.